Krystal Biotech (KRYS) PT Raised to $111 at Cowen

Cowen analyst Ritu Baral raised the price target on Krystal Biotech (NASDAQ: KRYS) to $111.00 (from $89.00) while maintaining an Outperform rating.

The analyst commented, "KRYS announced positive topline data from the Ph3 GEM-3 trial of Vyjuvek (fka B-VEC) in DEB. The study met its primary endpoint of 100% wound healing at 6 mo., with 67% of wounds treated with Vyjuvek achieving complete wound healing compared to 22% with pbo (absolute Δ 45.8%; p<0.005 by McNemar). Detailed data and BLA filing are expected in 1H22. We remain at Outperform, increasing our PT to $111."

You May Also Be Interested In

• Baker Hughes (BKR) PT Lowered to $36 at Cowen on Russia Wind Down
• Lending Tree (TREE) PT Lowered to $62 at Needham & Company
• Comcast Corp (CMCSA) PT Lowered to $44 at BofA Securities for 4 Reasons